Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6W5P4

UPID:
NPSR1_HUMAN

ALTERNATIVE NAMES:
G-protein coupled receptor 154; G-protein coupled receptor PGR14; G-protein coupled receptor for asthma susceptibility

ALTERNATIVE UPACC:
Q6W5P4; A2RTZ4; Q2XP58; Q56H76; Q56H77; Q56H78; Q6JSL4; Q6JSL5; Q6JSL6; Q6JSL7; Q6JSL8; Q6W5P3; Q6ZMB8

BACKGROUND:
The Neuropeptide S receptor, with aliases such as G-protein coupled receptor 154 and receptor for asthma susceptibility, is integral to cellular signaling. By binding to neuropeptide S, it triggers intracellular calcium mobilization and exerts an anti-proliferative effect. Its association with asthma and IgE-mediated diseases underscores its importance in immune system modulation.

THERAPEUTIC SIGNIFICANCE:
The therapeutic potential of the Neuropeptide S receptor in asthma and IgE-mediated conditions is immense. By elucidating the receptor's role in these diseases, researchers can pave the way for innovative treatments that could transform the lives of individuals suffering from asthma and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.